CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M

CV Sciences, Inc.

Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.
Gross margin improved to 49.0% from 45.6%; operating loss reduced to $0.5M from $2.2M.
Adjusted EBITDA loss was $0.3M, improved from $0.8M in 2024; Q4 2025 delivered positive adjusted EBITDA of $0.1M.
Cash balance $0.3M at year-end; completed debt restructuring in Q1 2026 to strengthen financial position.
Launched 39 new products since Jan 2023; new products contributed 39% of FY2025 net revenue.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CV Sciences, Inc. reported the year and quarter ended December 31, 2025 results: revenue $13.8 million.

Period: the year and quarter ended December 31, 2025
Revenue: $13.8 million
Result: reported results

Exact text from the filing

its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights • Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

CV Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126211

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.